72_CD
Company_NN
information_NOMZ
and_PHC
advisers_NN
COMPANY_NN
SECRETARY_NN
,_,
REGISTERED_NN
OFFICE_NN
AND_PHC
GROUP_NN
HEADQUARTERS_NN
ANNOUNCEMENTS_NOMZ
Elizabeth_NN
Brown_NN
First_NN
quarter_NN
results_NN
May_POMD
Peterhouse_NN
Technology_NN
Park_NN
Second_NN
quarter_NN
interim_JJ
results_NN
September_NN
100_CD
Fulbourn_NN
Road_NN
Third_NN
quarter_NN
results_NN
November_NN
Cambridge_NN
CB1_NN
9PT_NN
,_,
UK_NN
Final_NN
results_NN
March_NN
Telephone_NN
44_CD
0_CD
1223 275 300_CD
CORPORATE_JJ
ADVISERS_NN
Registered_NN
number_NN
2863682_CD
Legal_NN
advisers_NN
Date_NN
of_PIN
incorporation_NOMZ
19_CD
October_NN
1993_CD
Weil_NN
,_,
Gotshal_NN
&_CC
Manges_NN
Country_NN
of_PIN
jurisdiction_NOMZ
England_NN
and_PHC
Wales_NN
One_CD
South_NN
Place_NN
London_NN
EC2M_NN
2WG_NN
,_,
UK_NN
ACAMBIS_NN
US_FPP1
OPERATIONS_NOMZ
Acambis_NN
Inc._NN
._.
Bankers_NN
38_CD
Sidney_NN
Street_NN
Barclays_NN
Bank_NN
PLC_NN
Cambridge_NN
Corporate_NN
Banking_GER
Massachusetts_NN
02139_CD
,_,
USA_NN
PO_NN
Box_NN
885_CD
Telephone_NN
1_CD
617 761 4200_CD
Mortlock_NN
House_NN
Vision_NN
Park_NN
Berna_NN
Products_NN
Corporation_NOMZ
Histon_NN
4216_CD
Ponce_NN
fide_NN
Leon_NN
Boulevard_NN
Cambridge_NN
CB49DE_NN
,_,
UK_NN
Coral_NN
Gables_NN
Florida_NN
33146_CD
,_,
USA_NN
Registrars_NN
Telephone_NN
1_CD
800 392 9490_CD
Capita_NN
Registrars_NN
The_DT
Registry_NN
SHAREHOLDER_NN
INFORMATION_NOMZ
34_CD
Beckenham_NN
Road_NN
The_DT
share_NN
price_NN
is_VPRT [BEMA]
obtainable_PRED
in_PIN
most_EMPH
UK_NN
and_PHC
US_FPP1
national_JJ
newspapers_NN
Beckenham_NN
and_CC
on_PIN
Acambis_NN
website_NN
at_PIN
www_NN
._.
com_NN
Kent_NN
BR34TU_NN
,_,
UK_NN
London_NN
Stock_NN
Exchange_NN
mnemonic_JJ
ACM_NN
Auditors_NN
US_FPP1
NASDAQ_NN
National_NN
Market_NN
ticker_NN
symbol_NN
ACAM_NN
LLP_NN
Abacus_NN
House_NN
Reuters_NN
reference_NN
ACM_NN
._.
L_NN
Castle_NN
Park_NN
Cambridge_NN
CB30AN_NN
,_,
UK_NN
ANALYST_NN
COVERAGE_NN
OF_PIN
ACAMBIS_NN
ABN_NN
Amro_NN
Cazenove_NN
CODE_NN
Securities_NOMZ
Credit_NN
Suisse_NN
First_NN
Boston_NN
Deutsche_NN
Bank_NN
Evolution_NOMZ
Beeson_NN
Gregory_NN
Goldman_NN
Sachs_NN
ING_NN
Barings_GER
Jefferies_NN
KBC_NN
Peel_NN
Hunt_NN
Merrill_NN
Lynch_NN
Nomura_NN
Numis_NN
Panmure_NN
Gordon_NN
Teather_NN
&_CC
Greenwood_NN
UBS_NN
Warburg_NN
Index_NN
ACAM2000_NN
4_CD
,_,
11_CD
,_,
17_CD
,_,
22_CD
Fixed_VBN
asset_NN
investments_NOMZ
53_CD
,_,
57_CD
Staff_NN
costs_NN
54_CD
Accounting_GER
policies_NN
50_CD
Foreign_JJ
currencies_NN
52_CD
,_,
62_CD
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
46_CD
Administrative_JJ
costs_NN
53_CD
Stock_NN
47_CD
,_,
59_CD
ADR_NN
pricing_GER
25_CD
,_,
71_CD
Goodwill_NN
56_CD
Stock_NN
options_NOMZ
see_VPRT [PRIV]
Share_NN
options_NOMZ
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
71_CD
TM_NN
Substantial_NN
shareholdings_GER
70_CD
ARILVAX_NN
4_CD
,_,
17_CD
,_,
23_CD
Health_NN
and_PHC
safety_NN
21_CD
,_,
43_CD
Summarised_NN
Group_NN
statements_NOMZ
69_CD
Audit_NN
Committee_NN
30_CD
Auditors_NN
45_CD
,_,
54_CD
,_,
72_CD
Independent_NN
auditors_NN
report_VPRT [PUBV]
45_CD
Tangible_JJ
fixed_JJ
assets_NN
57_CD
Aventis_NN
Pasteur_NN
17_CD
Interest_NN
53_CD
Taxation_NOMZ
46_CD
,_,
55_CD
Internal_NN
control_NN
31_CD
Total_JJ
shareholder_NN
return_NN
41_CD
Balance_NN
sheets_NN
47_CD
,_,
48_CD
Investments_NOMZ
51_CD
,_,
57-58_CD
Trade_NN
investments_NOMZ
58_CD
Baxter_NN
11_CD
,_,
17_CD
,_,
23_CD
,_,
48_CD
Trading_GER
results_NN
24_CD
Berna_NN
Biotech_NN
17_CD
Japanese_JJ
encephalitis_NN
see_VPRT [PRIV]
ChimeriVax-JE_NN
Berna_NN
Products_NN
Corporation_NOMZ
7_CD
,_,
9_CD
,_,
22_CD
Joint_NN
venture_NN
61_CD
Vaccine_NN
market_NN
8-9_CD
,_,
16_CD
Board_NN
of_PIN
Directors_NN
14_CD
,_,
23_CD
,_,
26-27_CD
,_,
28_CD
VIG_NN
C-VIG_NN
4_CD
,_,
11_CD
,_,
22_CD
Leases_NN
52_CD
Vivotif_NN
4_CD
,_,
7_CD
,_,
17_CD
,_,
23_CD
Cangene_NN
Corporation_NOMZ
11_CD
,_,
17_CD
Canton_NN
see_VB [PRIV]
Manufacturing_GER
Manufacturing_GER
7_CD
West_NN
Nile_NN
see_VPRT [PRIV]
ChimeriVax-West_NN
Nile_NN
Capital_NN
expenditure_NN
25_CD
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
71_CD
Cash_NN
46_CD
MVA_NN
2_CD
,_,
9_CD
,_,
17_CD
,_,
22_CD
Acambis_NN
is_VPRT [BEMA]
a_DT
UK_NN
public_JJ
limited_JJ
company_NN
Cash_NN
flow_NN
49_CD
,_,
66_CD
with_PIN
shares_NN
listed_VBN [WZPAST]
on_PIN
the_DT
London_NN
Stock_NN
GOOD_NN
QUESTIONS_NOMZ
Exchange_NN
and_CC
,_,
in_PIN
the_DT
form_NN
of_PIN
American_JJ
Chairmans_NN
statement_NOMZ
2-3_CD
Nominations_NOMZ
Committee_NN
31_CD
2_CD
Chairmans_NN
statement_NOMZ
Depositary_NN
Receipts_NN
,_,
on_PIN
the_DT
NASDAQ_NN
national_JJ
Charitable_JJ
donations_NOMZ
42_CD
Notes_NN
to_PIN
Group_NN
financial_JJ
statements_NOMZ
50-68_JJ
market_NN
._.
This_DEMP
is_VPRT [BEMA]
the_DT
Annual_JJ
Report_NN
for_PIN
the_DT
4_CD
Company_NN
overview_NN
ChimeriVax-Dengue_NN
5_CD
,_,
17_CD
,_,
23_CD
year_NN
ended_VBD
31_CD
December_NN
2003_CD
._.
It_PIT
contains_VPRT
6_CD
Total_JJ
integration_NOMZ
ChimeriVax-JE_NN
4_CD
,_,
17_CD
,_,
23_CD
OFR_NN
16-25_CD
the_DT
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
8_CD
The_DT
vaccine_NN
market_NN
in_PIN
accordance_NN
with_PIN
UK_NN
regulations_NOMZ
._.
The_DT
ChimeriVax-West_NN
Nile_NN
5_CD
,_,
8_CD
,_,
17_CD
,_,
23_CD
Operating_GER
review_NN
22-23_CD
10_CD
The_DT
smallpox_NN
opportunity_NOMZ
Annual_JJ
Report_NN
on_PIN
Form_NN
20-F_NN
for_PIN
the_DT
US_FPP1
C._NN
difficile_NN
5_CD
,_,
17_CD
,_,
23_CD
Organisational_NN
structure_NN
48_CD
12_CD
The_DT
future_JJ
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
will_PRMD
Company_NN
information_NOMZ
and_PHC
advisers_NN
72_CD
be_VB [PASS]
filed_VBN
separately_RB
._.
References_NN
to_PIN
the_DT
Group_NN
14_CD
Interview_NN
Abbreviations_NOMZ
used_VBD
in_PIN
this_DEMO
document_NOMZ
Corporate_JJ
governance_NN
statement_NOMZ
28-33_CD
Products_NN
16_CD
,_,
17_CD
,_,
22_CD
and_CC
Acambis_NN
throughout_PIN
this_DEMO
document_NOMZ
ADR_NN
Accounting_GER
Principles_NN
Board_NN
relate_VPRT
to_PIN
Acambis_NN
plc_NN
and_CC
all_QUAN
of_PIN
its_PIT
subsidiary_NN
Corporate_JJ
social_JJ
responsibility_NOMZ
20-21_CD
,_,
42_CD
Profit_NN
and_PHC
loss_NN
account_NN
46_CD
BIA_NN
BioIndustry_NN
Association_NOMZ
THE_DT
STATEMENTS_NOMZ
and_CC
associated_VBN
undertakings_GER
._.
References_NN
BLA_NN
Biologics_NN
License_NN
Application_NOMZ
Creditors_NN
42_CD
,_,
47_CD
,_,
60_CD
Pensions_NN
35_CD
,_,
51_CD
,_,
67_CD
16_CD
Operating_GER
and_CC
financial_JJ
review_NN
to_PIN
the_DT
Company_NN
are_VPRT [BEMA]
to_PIN
Acambis_NN
plc_NN
,_,
the_DT
BPC_NN
Berna_NN
Products_NN
Corporation_NOMZ
Political_NN
donations_NOMZ
42_CD
26_CD
Board_NN
of_PIN
Directors_NN
ultimate_JJ
holding_VBG [PRIV]
company_NN
._.
CDC_NN
US_FPP1
Centers_NN
for_PIN
Disease_NN
Control_NN
Debtors_NN
47_CD
,_,
60_CD
Post_NN
balance_NN
sheet_NN
events_NN
43_CD
,_,
68_CD
28_CD
Corporate_JJ
governance_NN
overview_NN
and_PHC
Prevention_NOMZ
Cautionary_NN
statement_NOMZ
regarding_VBG [WZPRES]
EITF_NN
Emerging_VBG [WZPRES]
Issues_NN
Task_NN
Force_NN
30_CD
Corporate_JJ
governance_NN
statement_NOMZ
Dengue_NN
see_VB [PRIV]
ChimeriVax-Dengue_NN
forward-looking_JJ
statements_NOMZ
FASB_NN
Financial_NN
Accounting_GER
Standards_NN
34_CD
Remuneration_NOMZ
report_NN
Directors_NN
interests_NN
42_CD
,_,
55_CD
R&D_NN
4_CD
,_,
42_CD
Under_IN
the_DT
safe_JJ
harbor_NN
provisions_NN
of_PIN
the_DT
Board_NN
42_CD
Directors_NN
report_NN
Directors_NN
remuneration_VPRT
34-41_CD
,_,
55_CD
Registrars_NN
72_CD
US_FPP1
Private_NN
Securities_NOMZ
Litigation_NOMZ
Reform_NN
Act_NN
FDA_NN
US_FPP1
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
44_CD
Directors_NN
responsibilities_NOMZ
of_PIN
1995_CD
,_,
the_DT
Company_NN
cautions_VPRT
investors_NN
Directors_NN
report_VPRT [PUBV]
42_CD
Related_JJ
party_NN
transactions_NOMZ
68_CD
FIN_NN
FASB_NN
Interpretation_NOMZ
Number_NN
that_TOBJ
any_QUAN
forward-looking_JJ
statements_NOMZ
or_CC
45_CD
Independent_JJ
auditors_NN
report_VPRT [PUBV]
to_PIN
the_DT
members_NN
of_PIN
Acambis_NN
plc_NN
FRS_NN
Financial_NN
Reporting_GER
Standard_NN
Directors_NN
responsibilities_NOMZ
44_CD
Remuneration_NOMZ
Committee_NN
30_CD
projections_NOMZ
made_VBN [WZPAST]
in_PIN
this_DEMO
document_NOMZ
are_VPRT
IAS_NN
International_NN
Accounting_GER
Dividends_NN
42_CD
,_,
71_CD
Remuneration_NOMZ
report_NN
34-41_CD
subject_NN
to_PIN
risks_NN
and_PHC
uncertainties_NN
that_TSUB
may_POMD
Standard_NN
THE_DT
NUMBERS_NN
cause_VB
actual_JJ
results_NN
to_TO
differ_VB
materially_RB
Reserves_NN
65-66_CD
IFRS_NN
International_NN
Financial_NN
46_CD
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
from_PIN
those_DEMP
projected_VBN
._.
These_DEMO
forward-looking_JJ
Reporting_GER
Standards_NN
Earnings_GER
per_PIN
share_NN
56_CD
Risk_NN
factors_NN
19_CD
,_,
31-33_CD
46_CD
Group_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
statements_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
estimates_NN
and_PHC
IND_NN
Investigational_NN
New_NN
Drug_NN
Employees_NN
21_CD
,_,
25_CD
,_,
42_CD
assumptions_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
management_NOMZ
47_CD
Group_NN
balance_NN
sheet_NN
Application_NOMZ
Environment_NOMZ
21_CD
,_,
43_CD
Segmental_JJ
information_NOMZ
53_CD
of_PIN
Acambis_NN
and_CC
are_VPRT [PASS]
believed_VBN [PRIV]
to_TO
be_VB [BEMA]
reasonable_PRED
,_,
R&D_NN
Research_NN
and_PHC
development_NOMZ
48_CD
Company_NN
balance_NN
sheet_NN
though_CONC
are_VPRT [BEMA]
inherently_RB
uncertain_PRED
and_PHC
difficult_PRED
Exceptional_JJ
item_NN
53_CD
Selected_VBN
financial_JJ
information_NOMZ
69_CD
SEC_NN
US_FPP1
Securities_NOMZ
and_PHC
Exchange_NN
49_CD
Group_NN
cash_NN
flow_NN
statement_NOMZ
to_TO
predict_VB [PUBV]
._.
Actual_JJ
results_NN
or_CC
experience_NN
could_POMD
Commission_NN
Exchange_NN
rate_NN
information_NOMZ
57_CD
Share_NN
capital_NN
64-65_CD
50_CD
Notes_NN
to_PIN
Group_NN
financial_JJ
statements_NOMZ
differ_VPRT
materially_RB
from_PIN
the_DT
forward-looking_JJ
SFAS_NN
Statement_NOMZ
of_PIN
Financial_NN
Executive_NN
Committee_NN
31_CD
Share_NN
options_NOMZ
36-41_CD
,_,
52_CD
statements_NOMZ
._.
Factors_NN
that_TSUB
may_POMD
affect_VB
the_DT
Accounting_GER
Standard_NN
Share_NN
pricing_GER
71_CD
Groups_NN
operations_NOMZ
are_VPRT [PASS]
discussed_VBN
in_PIN
the_DT
UITF_NN
Urgent_NN
Issues_NN
Task_NN
Force_NN
GENERAL_NN
INFORMATION_NOMZ
operating_GER
and_CC
financial_JJ
review_NN
and_CC
the_DT
UK_NN
GAAP_NN
United_NN
Kingdom_NN
generally_RB
Financial_JJ
commitments_NOMZ
67_CD
Share_NN
register_NN
analysis_NN
70_CD
69_CD
Summarised_NN
Group_NN
statements_NOMZ
corporate_JJ
governance_NN
statement_NOMZ
contained_VBD
accepted_VBN [PRIV]
accounting_GER
principles_NN
Financial_JJ
instruments_NOMZ
22_CD
Shareholder_NN
information_NOMZ
70-71_CD
70_CD
Shareholder_NN
information_NOMZ
within_PIN
this_DEMO
Annual_JJ
Report_NN
and_CC
in_PIN
documents_NOMZ
US_FPP1
GAAP_NN
United_NN
States_NN
generally_RB
accepted_VBN [PRIV]
72_CD
Company_NN
information_NOMZ
and_PHC
advisers_NN
Financial_NN
review_NN
24-25_CD
Shareholders_NN
funds_NN
66_CD
as_IN
filed_VBN
with_PIN
the_DT
US_FPP1
Securities_NOMZ
and_PHC
Exchange_NN
accounting_GER
principles_NN
IBC_NN
Index_NN
WHO_WP [WHOBJ]
World_NN
Health_NN
Organization_NOMZ
Commission_NN
from_PIN
time_NN
to_PIN
time_NN
._.
Financial_NN
systems_NN
18_CD
Smallpox_NN
vaccine_NN
see_VPRT [PRIV]
ACAM2000_CD
in_PIN
collaboration_NOMZ
with_PIN
Crescent_NN
Lodge_NN
._.
Printed_NN
by_PIN
St_NN
Ives_NN
Westerham_NN
Press_NN
ACAMBIS_NN
PLC_NN
ANNUAL_NN
REPORT_NN
2003_CD
ACAMBIS_NN
PLC_NN
Peterhouse_NN
Technology_NN
Park_NN
100_CD
Fulbourn_NN
Road_NN
Cambridge_NN
CB1_NN
9PT_NN
United_NN
Kingdom_NN
Telephone_NN
44_CD
0_CD
1223 275 300_CD
Good_JJ
Fax_NN
44_CD
0_CD
1223 416 300_CD
Email_NN
acambis_VPRT
acambis_NN
._.
